Elutia (ELUT) Income from Continuing Operations (2019 - 2026)
Elutia's (ELUT) quarterly Income from Continuing Operations came in at -$7.6 million in Q2 2026, down 7.83% year-over-year from -$8.3 million in Q2 2025, and up 3.14% quarter-over-quarter from -$7.9 million in Q1 2026.
Analysis
Elutia (ELUT) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Elutia has disclosed Income from Continuing Operations across 8 years of filings, most recently posting -$7.6 million for Q2 2026.
- In Q2 2026, Income from Continuing Operations fell 7.83% year-over-year to -$7.6 million; the TTM figure through Jun 2026 stood at -$19.1 million (down 49.54% YoY), while the FY2025 annual figure was -$12.6 million, up 72.28% from the prior year.
- Income from Continuing Operations came in at -$7.6 million for Q2 2026 at Elutia, up from -$7.9 million in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of $3.3 million in Q3 2024 to a low of -$28.4 million in Q2 2024.
- Average Income from Continuing Operations over 5 years is -$8.6 million, with a median of -$7.8 million recorded in 2023.
- Year-over-year, Income from Continuing Operations surged 139.19% in 2024 and plunged 318.34% in 2026.
- Over 5 years, Income from Continuing Operations stood at -$6.0 million in 2022, then plunged by 153.07% to -$15.2 million in 2023, then surged by 53.0% to -$7.2 million in 2024, then jumped by 55.15% to -$3.2 million in 2025, then tumbled by 138.27% to -$7.6 million in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were -$7.6 million in Q2 2026, -$7.9 million in Q1 2026, and -$3.2 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.19 Bn | 175.58 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Intuitive Surgical | 127.77 Bn | 122.55 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Medtronic | 117.13 Bn | 108.31 Bn | 6.34 Bn | 1.48 Bn |
| 4 | Stryker | 104.67 Bn | 101.20 Bn | 4.50 Bn | 1.28 Bn |
| 5 | Boston Scientific | 64.48 Bn | 63.94 Bn | 3.85 Bn | 905.00 Mn |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 241.40 Mn |
| 7 | Alcon | 33.06 Bn | 31.61 Bn | 1.68 Bn | -92.00 Mn |
| 8 | Dexcom | 32.37 Bn | 30.43 Bn | 830.00 Mn | 249.10 Mn |
| 9 | Steris | 20.76 Bn | 20.28 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Elutia | 37.26 Mn | 17.36 Mn | 1.45 Mn | -7.65 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7.65 Mn |
| Mar 31, 2026 | -7.89 Mn |
| Dec 31, 2025 | -3.21 Mn |
| Sep 30, 2025 | -383,000.00 |
| Jun 30, 2025 | -7.09 Mn |
| Mar 31, 2025 | -1.89 Mn |
| Dec 31, 2024 | -7.16 Mn |
| Sep 30, 2024 | 3.34 Mn |
| Jun 30, 2024 | -28.36 Mn |
| Mar 31, 2024 | -17.99 Mn |
| Dec 31, 2023 | -15.22 Mn |
| Sep 30, 2023 | -8.52 Mn |
| Jun 30, 2023 | -7.73 Mn |
| Mar 31, 2023 | -9.78 Mn |
| Dec 31, 2022 | -6.02 Mn |
| Sep 30, 2022 | -11.03 Mn |
| Jun 30, 2022 | -9.40 Mn |
| Mar 31, 2022 | -8.15 Mn |
| Dec 31, 2021 | -9.06 Mn |
| Sep 30, 2021 | -8.32 Mn |